Therapeutic Anti-IGF-1r and Anti-TSHR bispecific antibody and use thereof
By developing bispecific antibodies targeting IGF-1R and TSHR, the limitations of existing drugs in treating Graves' eye disease and their side effects have been addressed, resulting in more effective treatment.
WO2025232704A1 Publication Date: 2025-11-13VELAVIGO BIO INC +1
5 Cites 1 Cited by
Patent Information
- Application Number
- PCT/CN2025/092756
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-24
- Filing Date
- 2025-05-05
- Publication Date
- 2025-11-13
AI Technical Summary
Technical Problem
Existing single IGF-1R antagonists and TSHR antagonists have limited efficacy and side effects in treating Graves' eye disease, such as hyperglycemia and hearing loss that may be caused by teprotumumab. There is a lack of effective dual-targeted drug solutions.
Method used
Develop bispecific antibodies targeting IGF-1R and TSHR, which bind to IGF-1R and TSHR through the VHH domain, blocking their signaling pathways and reducing the toxicity of high-dose drugs.
Benefits of technology
It effectively inhibits the interaction between IGF-1R and TSHR, reduces side effects, and provides a more effective treatment for Graves' ophthalmopathy.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided are a therapeutic anti-IGF-1R and anti-TSHR bispecific antibody and a use thereof. Specifically disclosed are a single-domain antibody against IGF-1R, a bispecific antibody against IGF-1R and TSHR, a nucleic acid encoding the single-domain antibody or the bispecific antibody, a vector comprising the nucleic acid, and a host cell comprising the nucleic acid or the vector. Also provided are a pharmaceutical composition and conjugate or immune fusion comprising the antibody, and a treatment method using the antibody.
Need to check novelty before this filing date? Find Prior Art